Quick10K

⚲

Guided Therapeutics

Filings

10-Q	2021-03-31	Filed 2021-05-21
10-K	2020-12-31	Filed 2021-04-07
10-Q	2020-09-30	Filed 2020-11-05
S-1	2020-09-10	Public Filing
10-Q	2020-06-30	Filed 2020-08-20
10-Q	2020-03-31	Filed 2020-07-07
10-K	2019-12-31	Filed 2020-04-20
10-Q	2019-09-30	Filed 2020-03-09
10-Q	2019-06-30	Filed 2020-02-11
10-Q	2019-03-31	Filed 2019-07-11
10-K	2018-12-31	Filed 2019-05-08
10-Q	2018-09-30	Filed 2018-11-14
10-Q	2018-06-30	Filed 2018-08-14
S-1	2018-06-14	Public Filing
10-Q	2018-03-31	Filed 2018-05-21
10-K	2017-12-31	Filed 2018-04-17
10-Q	2017-09-30	Filed 2017-11-20
10-Q	2017-06-30	Filed 2017-08-18
10-Q	2017-03-31	Filed 2017-05-22
10-K	2016-12-31	Filed 2017-03-22
10-Q	2016-09-30	Filed 2016-12-05
10-Q	2016-06-30	Filed 2016-08-17
10-Q	2016-03-31	Filed 2016-05-19
10-K	2015-12-31	Filed 2016-03-15
10-Q	2015-09-30	Filed 2015-11-12
10-Q	2015-06-30	Filed 2015-08-13
10-Q	2015-03-31	Filed 2015-05-13
10-K	2014-12-31	Filed 2015-03-25
10-Q	2014-09-30	Filed 2014-11-12
10-Q	2014-06-30	Filed 2014-08-13
10-Q	2014-03-31	Filed 2014-05-15
10-K	2013-12-31	Filed 2014-03-26
10-Q	2013-09-30	Filed 2013-11-13
10-Q	2013-06-30	Filed 2013-08-14
10-Q	2013-03-31	Filed 2013-05-14
10-K	2012-12-31	Filed 2013-03-27
10-Q	2012-09-30	Filed 2012-11-13
10-Q	2012-06-30	Filed 2012-08-14
10-Q	2012-03-31	Filed 2012-05-14
10-Q	2011-09-30	Filed 2011-11-14
10-Q	2011-06-30	Filed 2011-08-15
10-Q	2011-03-31	Filed 2011-05-16
10-K	2010-12-31	Filed 2011-03-30
10-Q	2010-09-30	Filed 2010-11-10
10-Q	2010-06-30	Filed 2010-08-12
10-Q	2010-03-31	Filed 2010-05-13
10-K	2009-12-31	Filed 2010-03-23

Reports

8-K	2020-09-16
8-K	2020-03-31
8-K	2020-03-31
8-K	2019-04-03
8-K	2018-11-14
8-K	2018-10-25
8-K	2018-08-31

Guided Therapeutics Financials

GTHP Metrics, Comps, Filings

Quarterly | Annual

Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin


Comps ($'000 TTM)	Market Cap	Gross Margin	EV/EBITDA	Ret on Assets	Assets	Liabilities	Revenue	G Profit	Net Income	EBITDA	EV
Aries I Acquisition Corp. (RAMMU)
024 Pharma (EEIG)
Beauty Health Co (VSPRW)
Aquarius I Acquisition Corp. (AQUI)
MIZUHO FINANCIAL GROUP INC (MZHOF)
Eucrates Biomedical Acquisition Corp. (EUCRW)
11 Good Energy (ELVN)
180 Life Sciences Corp. (ATNFW)
1347 Capital Corp (TFSC)
Avanti Acquisition Corp. (AVAN-WT)
CORDIA CORP (CORG)
FCCC INC (FCIC)
Biofrontera Inc. (BFRI)
Ameren Illinois Co (AILNP)
MITSUBISHI UFJ FINANCIAL GROUP INC (MBFJF)
Janus International Group, Inc. (JBI-WT)
23andMe Holding Co. (MEUSW)
OceanTech Acquisitions I Corp. (OTECU)
Palayan Resources, Inc. (PLYN)
ALABAMA POWER CO (APRCP)


Balance Sheet ($'000)	2011-06-30	2011-12-31	2012-03-31	2012-09-30	2012-12-31	2013-03-31	2013-06-30	2013-09-30	2013-12-31	2014-03-31	2014-06-30	2014-09-30	2014-12-31	2015-03-31	2015-06-30	2015-09-30	2015-12-31	2016-03-31	2016-06-30	2016-09-30	2016-12-31	2017-03-31	2017-06-30	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30	2018-12-31	2019-03-31
Cash	2,343	2,200	1,004	2,609	1,045	1,109	1,980	400	613	50	485	42	162	18	1,974	172	35	56	22	4	14	1	8	74	1	76	41	70	0	6
Accounts Receivable	149	117	38	65	107	166	177	112	133	122	233	417	338	358	282	219	190	230	289	226	0	41	4	0	3	5	6	4	13	13
Inventory				461	524	439	1	1	1,193	1	1,119	1,204	1,180	1,149	985	912	1,119	1,253	1,238	1,171	773	836	756	577	265	295	280	265	114	112
PP&E	64	1,033	1,088	1,270	2,220	1,263	1,137	1,030	2,327	807	804	706	2,432	515	444	2,435	2,440	2,440	217	2,441	2,441	2,441	2,441	2,441	2,441	2,441	2,441	2,441	2,441	2,426
Assets	3,318	4,310	3,085	4,771	3,478	3,585	4,396	2,931	3,316	2,596	3,822	3,722	3,031	2,560	4,037	2,767	2,563	2,366	2,313	2,060	1,492	1,492	1,508	905	489	527	418	491	236	404
Accounts Payable	937	1,102	863	1,040	765	878	986	822	891	1,268	1,063	1,664	1,733	1,563	1,963	1,466	1,824	1,977	2,208	2,450	2,600	2,748	2,888	2,965	3,019	2,976	2,961	2,971	3,013	3,004
Long-Term Debt	17	4	0	406		1,723	2,650	135		99	4	40		0	1,336	0		479											5,068	445
Liabilities	2,908	2,733	2,177	2,647	2,345		2,650	2,409	3,423	3,866	6,316	7,667	7,496	7,578	6,774	6,250	8,125	7,816	9,449	9,370	10,758	10,544	11,855	13,250	19,891	18,465	14,636	14,661	16,060	16,413
Stockholders' Equity	410	1,577			1,133				-107				-4,465				-5,562				-9,266				-19,402				-15,824


Income Statement ($'000)	2011-06-30	2011-12-31	2012-03-31	2012-09-30	2012-12-31	2013-03-31	2013-06-30	2013-09-30	2013-12-31	2014-03-31	2014-06-30	2014-09-30	2014-12-31	2015-03-31	2015-06-30	2015-09-30	2015-12-31	2016-03-31	2016-06-30	2016-09-30	2016-12-31	2017-03-31	2017-06-30	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30	2018-12-31	2019-03-31
Revenue	913		718	693	1,012	167	222	86	346	19	11	22	13	15	10	8	9	0						33		4	8	2		18
Cost of Revenue				705	999	193	225	145	510	89	81	19	9	-5	114	144	-239	-194						97		3	1	0		1
Gross Profit				-12	13	-26	-3	-59	-164	-70	-70	3	4	20	-104	-136	248	194	96	10	-189	5	5	-64	-228	1	74	2		17
R&D	619		714	787	830	813	860	596	499	607	635	892	666	373	305	413	387	290	148	87	208	91	96	69	83	69	63	43		47
SG&A	779		1,000	864	1,362	1,203	1,465	1,071	1,035	1,421	1,694	1,549	1,500	1,135	1,202	1,297	1,414	1,034	846	602	717	428	449	1,206	420	308	461	193		227
Tax
Net Income	-496		-1,013	-986	-1,187	-1,815	-1,750	-1,437	-2,213	-1,562	-2,152	-2,971	-3,198	-1,245	-1,706	-2,191	-1,758	130	-1,879	-211	-2,010	-107	-969	-2,365	-7,151	1,082	6,866	-743		-215


Cash Flow ($'000)	2011-06-30	2011-12-31	2012-03-31	2012-09-30	2012-12-31	2013-03-31	2013-06-30	2013-09-30	2013-12-31	2014-03-31	2014-06-30	2014-09-30	2014-12-31	2015-03-31	2015-06-30	2015-09-30	2015-12-31	2016-03-31	2016-06-30	2016-09-30	2016-12-31	2017-03-31	2017-06-30	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30	2018-12-31	2019-03-31
Cash Operating																									-663	-395	-242	-417		-186
Cash Investing			-130		-56	-101	0	-10	4	-4	-115	-25	-6	0	0	-2	-6	0			0
Cash Financing			124		41	1,479	2,331	115	1,306	400	2,415	1,565	1,602	482	2,524	596	322	976	550	48	207	394	-123	270	590	470	207	446		192